Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SHPH
SHPH logo

SHPH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.020
Open
0.960
VWAP
0.93
Vol
224.92K
Mkt Cap
4.95M
Low
0.881
Amount
208.93K
EV/EBITDA(TTM)
--
Total Shares
5.59M
EV
978.28K
EV/OCF(TTM)
--
P/S(TTM)
--
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Show More

Events Timeline

(ET)
2025-10-10
10:22:42
Shuttle Pharmaceuticals Reveals Extension of Letter of Intent with Molecule.ai
select
2025-10-09 (ET)
2025-10-09
16:23:14
Shuttle Pharmaceuticals to purchase Molecule.ai for $10 million
select
2025-06-12 (ET)
2025-06-12
12:01:37
Shuttle Pharmaceuticals says reverse stock split to become effective June 16
select
2025-06-12
08:40:46
Shuttle Pharmaceuticals announces 25-for-1 proposed reverse stock split
select
2025-06-04 (ET)
2025-06-04
16:08:28
Shuttle Pharmaceuticals appoints George Scorsis as chairman
select
2025-05-15 (ET)
2025-05-15
16:49:23
Shuttle Pharma Ropidoxuridine Phase 2 trial nears 50% enrollment
select
2025-04-10 (ET)
2025-04-10
16:06:34
Shuttle Pharmaceuticals files provisional patent application with USPTO
select
2025-03-12 (ET)
2025-03-12
09:26:58
Shuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offering
select
2025-03-12
06:21:55
Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO
select

News

seekingalpha
8.5
03-06seekingalpha
Shuttle Pharmaceuticals Announces Public Offering of Shares
  • Funding Size: Shuttle Pharmaceuticals has entered into a securities purchase agreement to issue 2.24 million shares of common stock and pre-funded warrants for an aggregate gross proceeds of approximately $3.50 million, indicating a significant capital market financing need.
  • Offering Details: The public offering is expected to close around March 9, 2026, suggesting the company is seeking financial support for future business development, even as its stock price fell by 13.92% in premarket trading.
  • Market Reaction: Following the announcement of the offering, Shuttle Pharmaceuticals' stock price dropped to $0.7476 in premarket trading, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
  • Strategic Implications: This financing will provide essential capital to address operational costs and R&D expenditures, and while the market response is negative, it may ultimately support the company's long-term growth objectives.
NASDAQ.COM
8.5
01-20NASDAQ.COM
Shuttle Pharmaceuticals (SHPH) Shares Surge 158% to $4.21 Amid AI-Driven Oncology Pipeline Interest
  • Stock Surge: Shuttle Pharmaceuticals' shares soared 158% in pre-market trading to $4.21, reflecting strong investor interest in its oncology pipeline and signaling confidence in the company's growth potential.
  • AI Integration: Recent regulatory approval for AI-based prescriptions in Utah highlights the strategic importance of Shuttle's use of the Molecule.ai platform in drug discovery, which is expected to reduce costs and accelerate the identification of new drug candidates.
  • Pipeline Overview: The company's pipeline includes investigational candidates like Ropidoxuridine (ROPES) and SP-2, aimed at enhancing radiation therapy effectiveness and working alongside immunotherapies to strengthen tumor response, supporting precision medicine initiatives.
  • Stock Performance History: SHPH has traded between $1.52 and $25.25 over the past year, with the latest data showing a closing price of $1.63 on January 16, 2026, up 10.14% from the previous day.
Yahoo Finance
8.5
01-13Yahoo Finance
Shuttle Pharma Applauds Utah's AI Prescription Refill System, Enhancing Healthcare Efficiency
  • AI Prescription Innovation: Utah becomes the first state in the U.S. to allow AI systems to authorize prescription refills without direct physician involvement, marking a significant advancement in reducing healthcare costs, eliminating delays, and expanding access to care.
  • Enhanced Drug Discovery Efficiency: Shuttle Pharma's Molecule.ai platform applies AI technology to significantly shorten the time to identify viable drug candidates and reduce the costs of failed experiments, transforming what once took months of manual experimentation into just days, thereby greatly improving R&D efficiency.
  • Regulatory and Safety Measures: The Molecule.ai platform incorporates uncertainty quantification and human-in-the-loop workflows to ensure expert oversight at critical decision points, enhancing the safety and reliability of AI in drug discovery.
  • Future Policy Implications: Results from Utah's AI prescription pilot program will guide future state and federal AI policies, potentially serving as a national model for high-stakes AI regulation in healthcare, driving demand for robust AI platforms in the industry.
NASDAQ.COM
5.0
2025-11-29NASDAQ.COM
Shuttle Pharma Names Christopher Cooper as Acting CFO
  • CFO Resignation: Timothy Lorber has resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. effective November 21, 2025.

  • Interim CFO Appointment: Christopher Cooper, the current Interim Chief Executive Officer, has taken over the role of Chief Financial Officer.

  • Search for Permanent CFO: The company is actively searching for a permanent Chief Financial Officer to fill the position.

  • Disclaimer: The views expressed in the article do not necessarily reflect those of Nasdaq, Inc.

Benzinga
9.5
2025-11-24Benzinga
LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading
  • LexinFintech Holdings Performance: LexinFintech Holdings Ltd reported a significant increase in quarterly earnings, rising to 43 cents per share from 28 cents a year ago, despite a drop in sales to $367.580 million from $521.851 million. The stock surged 15.3% in pre-market trading.

  • Other Gainers in Pre-Market Trading: Several stocks saw notable increases in pre-market trading, including Inspire Veterinary Partners Inc (+54.4%), VisionSys AI Inc (+43.4%), and JX Luxventure Group Inc (+36.2%).

  • Losers in Pre-Market Trading: Conversely, stocks like Clearside Biomedical Inc (-50.3%), Shuttle Pharmaceuticals Holdings Inc (-15%), and XChange TEC.INC (-14%) experienced significant declines in pre-market trading.

  • Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific percentage changes.

Benzinga
2.0
2025-11-21Benzinga
What Caused the Overnight Surge in Shuttle Pharmaceuticals (SHPH) Stock?
  • Stock Performance: Shuttle Pharmaceuticals Holdings Inc. (SHPH) saw a 27.87% increase in after-hours trading, reaching $2.34, despite closing down 7.58% at $1.83 during regular trading. The stock is down 91.4% year-to-date.

  • S-1 Registration Statement: The company filed a Form S-1 registration statement with the SEC for the resale of 625,156 common shares linked to a pre-funded warrant with a $0.001 exercise price.

  • Private Placement: Shuttle Pharmaceuticals completed a private placement on November 4, generating approximately $2.5 million in gross proceeds from an accredited investor, with WestPark Capital Inc. acting as the placement agent.

  • Market Capitalization: As of Monday, the company had 1,603,285 outstanding shares and a market capitalization of $2.93 million, with the filing indicating that it will not receive proceeds from the selling stockholder’s share sales.

Valuation Metrics

The current forward P/E ratio for Shuttle Pharmaceuticals Holdings Inc (SHPH.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Shuttle Pharmaceuticals Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

What stocks unfer $10.00 are surging now
Intellectia · 207 candidates
Price: $0.10 - $10.00List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
GITS logo
GITS
Global Interactive Technologies Inc
7.20M
DRCT logo
DRCT
Direct Digital Holdings Inc
4.03M
LSTA logo
LSTA
Lisata Therapeutics Inc
35.81M
ACRS logo
ACRS
Aclaris Therapeutics Inc
490.80M
CAPT logo
CAPT
Captivision Inc
24.18M
SHPH logo
SHPH
Shuttle Pharmaceuticals Holdings Inc
4.81M

Whales Holding SHPH

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Shuttle Pharmaceuticals Holdings Inc (SHPH) stock price today?

The current price of SHPH is 0.8854 USD — it has decreased -10.61

What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s business?

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.

What is the price predicton of SHPH Stock?

Wall Street analysts forecast SHPH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SHPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s revenue for the last quarter?

Shuttle Pharmaceuticals Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Shuttle Pharmaceuticals Holdings Inc (SHPH)'s earnings per share (EPS) for the last quarter?

Shuttle Pharmaceuticals Holdings Inc. EPS for the last quarter amounts to -1.05 USD, decreased -97.35

How many employees does Shuttle Pharmaceuticals Holdings Inc (SHPH). have?

Shuttle Pharmaceuticals Holdings Inc (SHPH) has 9 emplpoyees as of March 11 2026.

What is Shuttle Pharmaceuticals Holdings Inc (SHPH) market cap?

Today SHPH has the market capitalization of 4.95M USD.